See more : Tata Elxsi Limited (TATAELXSI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of GT Biopharma, Inc. (GTBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GT Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Poolia AB (publ) (POOL-B.ST) Income Statement Analysis – Financial Results
- Altai Resources Inc. (ARSEF) Income Statement Analysis – Financial Results
- CANADIAN LARGE CAP LEADERS SPLI (NPS.TO) Income Statement Analysis – Financial Results
- DMG Blockchain Solutions Inc. (DMGGF) Income Statement Analysis – Financial Results
- Stemtech Corporation (STEK) Income Statement Analysis – Financial Results
GT Biopharma, Inc. (GTBP)
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.00K | 61.00K | 368.00K | 342.00K | 26.00K | 11.00K | 48.00K | 1.14M | 6.05M | 5.78M | 2.50M | 2.36M | 2.74M | 2.05M | 2.97M | 3.54M | 7.17M | 5.10M | 5.10M | 4.90M | 5.10M | 3.50M | 3.00M | 2.80M | 2.70M | 4.80M | 5.10M | 3.20M | 2.30M | 3.00M | 2.40M | 4.16M | 3.83M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 57.00K | 226.00K | 94.00K | 48.00K | 65.00K | 50.00K | 909.00K | 3.26M | 3.08M | 1.35M | 1.22M | 1.50M | 1.14M | 2.43M | 2.62M | 5.05M | 2.60M | 2.00M | 1.60M | 1.60M | 1.50M | 1.20M | 1.20M | 1.00M | 1.90M | 2.10M | 1.20M | 500.00K | 1.10M | 900.00K | 2.33M | 2.28M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -4.00K | -7.00K | -2.00K | -1.00K | 25.00K | 4.00K | 142.00K | 248.00K | -22.00K | -54.00K | -2.00K | 234.00K | 2.79M | 2.69M | 1.15M | 1.15M | 1.24M | 910.00K | 538.00K | 924.00K | 2.11M | 2.50M | 3.10M | 3.30M | 3.50M | 2.00M | 1.80M | 1.60M | 1.70M | 2.90M | 3.00M | 2.00M | 1.80M | 1.90M | 1.50M | 1.83M | 1.55M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 92.59% | 6.56% | 38.59% | 72.51% | -84.62% | -490.91% | -4.17% | 20.47% | 46.09% | 46.61% | 46.14% | 48.56% | 45.40% | 44.39% | 18.13% | 26.10% | 29.50% | 49.02% | 60.78% | 67.35% | 68.63% | 57.14% | 60.00% | 57.14% | 62.96% | 60.42% | 58.82% | 62.50% | 78.26% | 63.33% | 62.50% | 43.99% | 40.47% |
| Research & Development | 6.47M | 8.81M | 9.59M | 485.00K | 1.67M | 9.07M | 1.07M | 975.00K | 1.00M | 0.00 | 0.00 | 0.00 | 17.00K | 179.00K | 0.00 | 44.00K | 1.04M | 708.00K | 499.00K | 236.00K | 369.00K | 463.00K | 762.00K | 1.91M | 2.40M | 4.40M | 4.30M | 4.90M | 4.30M | 1.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.00K | 400.00K |
| General & Administrative | 0.00 | 0.00 | 47.92M | 6.28M | 9.79M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 935.00K | 3.36M | 3.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.13M | 1.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.11M | 12.45M | 47.92M | 6.28M | 9.79M | 12.49M | 134.50M | 8.40M | 7.95M | 2.40M | 935.00K | 3.76M | 3.89M | 2.26M | 1.15M | 1.40M | 2.87M | 4.65M | 2.34M | 2.03M | 1.65M | 1.26M | 2.29M | 3.30M | 3.29M | 3.60M | 2.60M | 2.80M | 3.30M | 1.70M | 3.40M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.13M | 1.19M |
| Other Expenses | 0.00 | 0.00 | -242.76K | -12.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 155.00K | 0.00 | 0.00 | 0.00 | 942.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.40M | 935.00K | 3.76M | 3.91M | 2.44M | 1.15M | 1.45M | 3.90M | 5.36M | 2.84M | 2.26M | 2.02M | 1.72M | 3.99M | 5.65M | 6.52M | 9.60M | 8.10M | 9.10M | 9.00M | 4.00M | 3.50M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.72M | 1.60M |
| Cost & Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.46M | 1.16M | 3.86M | 3.95M | 2.51M | 1.20M | 2.35M | 7.17M | 8.45M | 4.19M | 3.48M | 3.51M | 2.86M | 6.42M | 8.27M | 11.58M | 12.20M | 10.10M | 10.70M | 10.60M | 5.50M | 4.70M | 3.30M | 3.20M | 4.30M | 4.60M | 3.30M | 2.10M | 3.60M | 3.20M | 4.05M | 3.88M |
| Interest Income | 567.00K | 292.00K | 38.00K | 3.32K | 2.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 0.00 | 52.00K | 80.00K | 110.00K | 1.00K | 1.00K | 7.00K | 29.00K | 180.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 8.00K | 718.00K | 3.32M | 2.13M | 9.12M | 8.60M | 6.56M | 17.04M | 5.15M | 1.20M | 1.65M | 556.00K | 513.00K | 1.14M | 1.66M | 1.01M | 2.16M | 26.00K | 101.00K | 14.00K | 18.00K | 14.00K | 90.00K | 0.00 | 300.00K | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 290.00K | 210.00K |
| Depreciation & Amortization | 13.58M | 21.26M | 57.52M | 4.00K | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 22.00K | 2.00K | 3.00K | 23.00K | 31.00K | 55.00K | 251.00K | 893.00K | 301.00K | 154.00K | 785.00K | 177.00K | 282.00K | 412.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | -300.00K | -300.00K | -300.00K | -300.00K | -200.00K | 100.00K | -200.00K | -300.00K | 790.00K | 480.00K |
| EBITDA | 5.98M | 0.00 | 0.00 | -24.98M | -11.45M | -250.06M | -135.57M | -9.37M | -8.93M | -2.37M | -791.00K | -3.61M | -3.12M | -2.45M | -1.06M | -822.00K | -223.00K | -2.37M | -1.54M | -1.72M | -596.00K | -529.00K | -3.04M | -4.28M | -3.57M | -5.50M | -3.80M | -4.50M | -4.10M | -1.40M | -1.60M | -800.00K | -800.00K | 200.00K | 200.00K | -300.00K | 200.00K | -800.00K | -1.10M | 890.00K | 430.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,055.56% | -3,891.80% | -602.17% | -1,026.61% | -15,019.23% | -22,418.18% | -2,285.42% | -83.99% | -48.64% | -42.64% | -1.56% | 47.08% | -22.04% | -25.80% | -68.80% | -120.99% | -50.65% | -113.73% | -76.47% | -89.80% | -15.69% | 62.86% | -60.00% | -28.57% | -29.63% | 4.17% | 3.92% | -9.38% | 13.04% | -26.67% | -45.83% | 21.39% | 11.23% |
| Operating Income | -13.58M | -21.26M | -57.52M | -6.76M | -16.06M | -250.07M | -135.57M | -9.37M | -8.93M | -2.40M | -793.00K | -3.51M | -3.93M | -2.50M | -1.16M | -1.21M | -1.12M | -2.67M | -3.19M | -1.72M | -773.00K | -811.00K | -3.45M | -4.73M | -4.41M | -7.10M | -5.00M | -5.80M | -5.50M | -2.00M | -1.70M | -500.00K | -500.00K | 500.00K | 500.00K | -100.00K | 200.00K | -600.00K | -800.00K | 100.00K | -50.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,062.96% | -3,927.87% | -215.49% | -1,027.49% | -15,107.69% | -22,700.00% | -2,408.33% | -105.95% | -18.45% | -46.23% | -127.71% | -72.72% | -28.21% | -39.56% | -116.34% | -133.50% | -61.55% | -139.22% | -98.04% | -118.37% | -107.84% | -57.14% | -56.67% | -17.86% | -18.52% | 10.42% | 9.80% | -3.13% | 8.70% | -20.00% | -33.33% | 2.40% | -1.31% |
| Total Other Income/Expenses | 5.98M | 373.00K | -498.00K | -21.53M | -22.59M | -9.12M | -7.68M | 19.14M | -12.53M | -21.11M | 229.00K | -1.75M | 228.00K | -498.00K | -1.09M | -1.50M | 1.49M | -1.98M | 82.00K | -937.00K | -5.00K | -11.00K | -999.00K | 0.00 | 57.00K | 300.00K | 100.00K | 0.00 | -3.30M | -3.60M | 200.00K | 300.00K | 300.00K | 300.00K | 300.00K | 200.00K | 200.00K | 200.00K | 300.00K | 290.00K | 210.00K |
| Income Before Tax | -7.60M | -20.88M | -58.01M | -28.30M | -38.65M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -564.00K | -5.26M | -3.70M | -3.00M | -2.25M | -2.71M | 546.00K | 4.82M | -3.11M | -2.66M | -778.00K | -822.00K | -4.45M | 0.00 | -4.35M | -6.80M | -4.90M | 0.00 | -8.80M | -5.60M | -1.50M | -200.00K | -200.00K | 800.00K | 800.00K | 100.00K | 400.00K | -400.00K | -500.00K | 390.00K | 160.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -153.26% | -1,538.30% | -14,230.77% | -27,227.27% | -4,679.17% | -237.01% | 9.03% | 83.45% | -124.43% | -112.35% | -28.39% | -40.10% | -150.00% | 0.00% | -60.75% | -133.33% | -96.08% | 0.00% | -172.55% | -160.00% | -50.00% | -7.14% | -7.41% | 16.67% | 15.69% | 3.13% | 17.39% | -13.33% | -20.83% | 9.38% | 4.18% |
| Income Tax Expense | 0.00 | -381.00K | 680.00K | 3.32M | 2.13M | -228.52M | 7.68M | -30.41M | 17.04M | 5.15M | -292.00K | 1.56M | 556.00K | 513.00K | 1.14M | 77.00K | 75.00K | 120.00K | 2.00K | 1.54M | 13.00K | 0.00 | 42.00K | -42.00K | 85.00K | 0.00 | 200.00K | 200.00K | 3.40M | 3.60M | -200.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 180.00K | 70.00K |
| Net Income | -7.60M | -20.50M | -58.69M | -31.62M | -40.78M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -501.00K | -5.17M | -3.70M | -3.00M | -2.25M | -5.01M | 471.00K | -4.94M | -3.11M | -2.66M | -791.00K | -822.00K | -3.50M | -4.68M | -4.50M | -7.10M | -5.20M | -6.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 900.00K | 700.00K | 100.00K | 300.00K | -400.00K | -300.00K | 420.00K | 150.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -136.14% | -1,511.99% | -14,230.77% | -27,227.27% | -4,679.17% | -437.97% | 7.79% | -85.53% | -124.51% | -112.35% | -28.87% | -40.10% | -117.76% | -132.32% | -62.74% | -139.22% | -101.96% | -122.45% | -174.51% | -160.00% | -50.00% | -10.71% | -7.41% | 18.75% | 13.73% | 3.13% | 13.04% | -13.33% | -12.50% | 10.10% | 3.92% |
| EPS | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| EPS Diluted | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| Weighted Avg Shares Out | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
| Weighted Avg Shares Out (Dil) | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021
Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Hot Penny Stocks To Watch After The 1,100% SGOC Stock Rally
Are traders searching for penny stocks with certain technical traits like SGOC has? The post 4 Hot Penny Stocks To Watch After The 1,100% SGOC Stock Rally appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Former Penny Stocks To Watch This Week As Earnings Season Kicks Off
Why Focus On Penny Stocks? Here Are A Few That Give A Great Answer To That Question.
GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota
Deepening relationship between GT Biopharma and Dr. Jeffrey Miller TriKE™ improves FT538 iPSC NK cells from Fate Therapeutics in prostate cancer model GTB-3550 continues to demonstrate clinical success without significant toxicities BEVERLY HILLS, Calif., July 7, 2021 /PRNewswire/ -- GT Biopharma,...
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.
Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now
Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List?
7 Hot Penny Stocks Analysts Like To Watch In 2021
Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290%
Do you agree with analysts on these penny stocks? The post 9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit
BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic...
Source: https://incomestatements.info
Category: Stock Reports